Richard Wieland is a senior financial executive with over 35 years of experience in both public and private life science companies. He has held CFO positions at several companies and completed over 20 capital raising transactions totaling over $830 million. Wieland has broad experience leading finance, accounting, human resources, risk management, and information technology functions. Most recently, he was Executive Vice President and CFO of Unilife Corporation, a medical device company. He has an MBA from Washington University and an undergraduate degree in accounting and economics.

1. R. Richard Wieland II
10 Ambrose Lane
Barrington, IL 60010
717-487-5320 cell
rrwieland@comcast.net
www.LinkedIn.com/in/richardwieland
Richard Wieland is a senior financial executive with a diversified Life Science business background
that has involved both line and staff experience and more than thirty five years of business experience
in both public and private companies working with the Audit, Compensation and Governance
committees of the Board. He completed over twenty capital transactions raising over $830 million
including two successful IPOs and eleven M&A transactions. Subsequent to several M&A
transactions, he successfully managed the post-acquisition integration programs. He is a partner to
the CEO, interacts effectively with Boards of Directors and is skilled at working with operating
personnel in a team-oriented environment. In addition to his broad experience in leading the finance
and accounting functions, Rich also has also lead the Human Resource, Risk Management and
Information Technology functions. In addition to managing the finance and accounting functions, Rich
has also served on the Board of a NASDAQ company.
Until recently Rich was Executive Vice President and Chief Financial officer of Unilife Corporation, a
NASDAQ-traded medical device company that has a platform of various advanced drug delivery
devices that large pharmaceutical companies use to deliver their drugs to the healthcare marketplace.
Prior to Unilife he spent six years at two biotech companies in the drug discovery and development
field both of whom had products in clinical development.
Prior to that Rich had P&L responsibility for two healthcare companies and was a member of the
Board of Directors at one of them, Option Care Inc., a NASDAQ-traded home healthcare company
that was subsequently acquired by Walgreen’s
His first CFO position was with LyphoMed Inc., a generic pharmaceutical company. Over an eight
year period LyphoMed grew revenues at an average growth rate of 50+ % a year to $250 million
before being acquired by Fujisawa Pharmaceutical Co. Ltd. for approximately $1 billion. During this
time, Rich had very broad responsibilities, working closely with both the EVP of Sales & Marketing
and the EVP of manufacturing as well as P&L responsibility for the Company’s distribution operation
in Canada.
Rich started his career by spending eight years in the financial management program at Procter &
Gamble with the majority of time completing three different assignments within the Paper Division
which had revenues of approximately $9 billion. Following P&G, he held the VP - Controller position
at Oak Technology Inc. a wholly-owned subsidiary of Oak Industries, a Fortune 500 NYSE company
located in San Diego. Oak Technology was a $350 million, multi-national Company with twenty two
separate entities (50% International) that manufactured electronic components, controls and
materials. For these four years Rich also had the opportunity to work directly with the general
management of seven of the twenty two companies and regularly presented the operating results of
these companies to the Oak Industries Board.
Rich earned an MBA degree in finance from the Olin School of Business at Washington University
and an undergraduate degree in accounting and economics from Monmouth College. He is married
and has two adult daughters, one a partner in healthcare law firm and one a pediatric nurse, both
residing in Chicago. Rich was a member of the Signal Corps in the Army and served on the Alumni

2. Board of Monmouth College. After Fujisawa acquired LyphoMed, he established the Wieland Family
Foundation that supports charities for disadvantaged children.